Annabel Samimy
Stock Analyst at Stifel
(4.56)
# 282
Out of 4,413 analysts
39
Total ratings
52.17%
Success rate
39.84%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Buy | $40 | $16.05 | +149.22% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $75.42 | +6.07% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $111.22 | +106.80% | 3 | Mar 15, 2024 | |
| EOLS Evolus | Reiterates: Buy | $23 → $25 | $11.71 | +113.49% | 1 | Mar 8, 2024 | |
| IVA Inventiva | Maintains: Buy | $27 → $25 | $3.24 | +671.60% | 2 | Feb 16, 2024 | |
| OCS Oculis Holding AG | Initiates: Buy | $35 | $12.73 | +174.94% | 1 | Oct 5, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $60 → $65 | $47.84 | +35.87% | 3 | Aug 29, 2023 | |
| CARA Cara Therapeutics | Reiterates: Buy | $28 | $0.76 | +3,606.15% | 2 | Jun 27, 2023 | |
| FGEN FibroGen | Downgrades: Hold | $28 → $11 | $1.09 | +909.17% | 3 | Jun 26, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $45 | $12.37 | +263.78% | 1 | Mar 7, 2023 | |
| CLSD Clearside Biomedical | Upgrades: Buy | $8 | $1.29 | +520.16% | 1 | Nov 10, 2022 | |
| EVFM Evofem Biosciences | Downgrades: Hold | $375 → $63 | $0.01 | +422,197.30% | 2 | Oct 13, 2022 | |
| RANI Rani Therapeutics Holdings | Initiates: Buy | n/a | $6.70 | - | 1 | Aug 24, 2021 | |
| CALT Calliditas Therapeutics AB (publ) | Initiates: Buy | n/a | $18.65 | - | 1 | Jun 30, 2020 | |
| RDUS Radius Health | Initiates: Hold | n/a | $17.99 | - | 1 | Apr 24, 2020 | |
| TXMD TherapeuticsMD | Maintains: Buy | n/a | $1.89 | - | 2 | Apr 16, 2020 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | n/a | $30.60 | - | 4 | Apr 16, 2020 | |
| RVNC Revance Therapeutics | Maintains: Buy | n/a | $3.69 | - | 1 | Apr 16, 2020 | |
| DRRX DURECT | Downgrades: Hold | n/a | $0.95 | - | 2 | Oct 20, 2017 |
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $16.05
Upside: +149.22%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $75.42
Upside: +6.07%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $111.22
Upside: +106.80%
Evolus
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $11.71
Upside: +113.49%
Inventiva
Feb 16, 2024
Maintains: Buy
Price Target: $27 → $25
Current: $3.24
Upside: +671.60%
Oculis Holding AG
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $12.73
Upside: +174.94%
Apellis Pharmaceuticals
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $47.84
Upside: +35.87%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $28
Current: $0.76
Upside: +3,606.15%
FibroGen
Jun 26, 2023
Downgrades: Hold
Price Target: $28 → $11
Current: $1.09
Upside: +909.17%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $12.37
Upside: +263.78%
Clearside Biomedical
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $1.29
Upside: +520.16%
Evofem Biosciences
Oct 13, 2022
Downgrades: Hold
Price Target: $375 → $63
Current: $0.01
Upside: +422,197.30%
Rani Therapeutics Holdings
Aug 24, 2021
Initiates: Buy
Price Target: n/a
Current: $6.70
Upside: -
Calliditas Therapeutics AB (publ)
Jun 30, 2020
Initiates: Buy
Price Target: n/a
Current: $18.65
Upside: -
Radius Health
Apr 24, 2020
Initiates: Hold
Price Target: n/a
Current: $17.99
Upside: -
TherapeuticsMD
Apr 16, 2020
Maintains: Buy
Price Target: n/a
Current: $1.89
Upside: -
Supernus Pharmaceuticals
Apr 16, 2020
Maintains: Hold
Price Target: n/a
Current: $30.60
Upside: -
Revance Therapeutics
Apr 16, 2020
Maintains: Buy
Price Target: n/a
Current: $3.69
Upside: -
DURECT
Oct 20, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.95
Upside: -